Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014;10(5):1391-5.
doi: 10.4161/hv.28001. Epub 2014 Feb 19.

Toward a mechanism-based in vitro safety test for pertussis toxin

Stefan F C Vaessen  1 , Martijn W P Bruysters  2 , Rob J Vandebriel  2 , Saertje Verkoeijen  1 , Rogier Bos  3 , Cyrille A M Krul  1 , Arnoud M Akkermans  2
Affiliations
Review

Toward a mechanism-based in vitro safety test for pertussis toxin

Stefan F C Vaessen et al. Hum Vaccin Immunother. 2014.

Abstract

Pertussis vaccines are routinely administered to infants to protect them from whooping cough. Still, an adequate safety test for pertussis toxin (PT), one of the main antigens in these vaccines, is not available. The histamine sensitization test is currently the only assay accepted by regulatory authorities to test for the absence of active PT in vaccines. This is however, a lethal animal test with poor reproducibility. In addition, it is not clear whether the assumed underlying mechanism, i.e., ADP-ribosylation of G proteins, is the only effect that should be considered in safety evaluation of PT. The in vitro safety test for PT that we developed is based on the clinical effects of PT in humans. For this, human cell lines were chosen based on the cell types involved in the clinical effects of PT. These cell lines were exposed to PT and analyzed by microarray. In this review, we discuss the clinical effects of PT and the mechanisms that underlie them. The approach taken may provide as an example for other situations in which an in vitro assay based on clinical effects in humans is required.

Keywords: in vitro; microarray; pertussis toxin; safety; vaccine.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Mattoo S, Cherry JD. . Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 2005; 18:326 - 82; http://dx.doi.org/10.1128/CMR.18.2.326-382.2005; PMID: 15831828 - DOI - PMC - PubMed
    1. Tamura M, Nogimori K, Murai S, Yajima M, Ito K, Katada T, Ui M, Ishii S. . Subunit structure of islet-activating protein, pertussis toxin, in conformity with the A-B model. Biochemistry 1982; 21:5516 - 22; http://dx.doi.org/10.1021/bi00265a021; PMID: 6293544 - DOI - PubMed
    1. Guidelines for the production and control of the acellular pertussis component of monovalent of combined vaccines. WHO Technical Reports Series, WHO 1998; 878:57 - 72 - PubMed
    1. Pertussis vaccine (acellular, component, adsorbed). Eur.Pharmacopeia 2005:686-690.
    1. Pertussis vaccine. US Code of Federal Regulations, DC, USA, Government Printing Office 1983;58-61.

LinkOut - more resources